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Bone tissue engineering is a promising therapeutic alternative for bone grafting of large skeletal defects.
It generally comprises an ex vivo engineered combination of a carrier structure, stem/progenitor cells and
growth factors. However, the success of these regenerative implants largely depends on how well
implanted cells will adapt to the hostile and hypoxic host environment they encounter after implanta-
tion. In this review, we will discuss how hypoxia signalling may be used to improve bone regeneration in
a tissue-engineered construct. First, hypoxia signalling induces angiogenesis which increases the survival
of the implanted cells as well as stimulates bone formation. Second, hypoxia signalling has also
angiogenesis-independent effects on mesenchymal cells in vitro, offering exciting new possibilities to
improve tissue-engineered bone regeneration in vivo. In addition, studies in other ﬁelds have shown that
beneﬁts of modulating hypoxia signalling include enhanced cell survival, proliferation and differentia-
tion, culminating in a more potent regenerative implant. Finally, the stimulation of endochondral bone
formation as a physiological pathway to circumvent the harmful effects of hypoxia will be brieﬂy touched
upon. Thus, angiogenic dependent and independent processes may counteract the deleterious hypoxic
effects and we will discuss several therapeutic strategies that may be combined to withstand the hypoxia
upon implantation and improve bone regeneration.
© 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Tissue engineering aims to offer large-scale replacement of
damaged organs using implants generated from a combination of
cells, growth factors and an appropriate scaffold. The engineering of
bone tissue is a promising therapeutic strategy for non-healing
large bone defects, as autologous bone transplants, the current
gold standard, are limited in quantity and often associated with
donor-site morbidity. A key challenge in the clinical application of
cell-based tissue-engineered bone implants is the poor diffusion of
oxygen into avascular tissue, which is limited to 200 mm at most,
necessitating a functional blood vessel network to bring oxygen
into larger constructs (Ma et al., 2014b). However, the blood vessels
at the implant site are in most cases disrupted by the trauma or
surgery that caused the bone defect, leading to hypoxia or even
anoxia within the implant. This impaired oxygenation and nutrientExperimental Endocrinology,
(G. Carmeliet).
rved.
., et al., Targeting the hypoxic
, Molecular and Cellular Endosupply may lead to low cell survival and failure of the implant.
Indeed, studies in cardiac tissues have shown that tissue-
engineered constructs of clinically relevant size are devoid of ox-
ygen in the centre, causing massive loss of cell viability and
regenerative capacity (Radisic et al., 2006). Analogous herewith,
necrotic cells are observed in the centre of implanted large bone
constructs (Scheuﬂer et al., 2008). On the other hand, bone cells
have the capacity to withstand the temporary hypoxia that occurs
during certain stages of bone development or uncomplicated
fracture repair (Drager et al., 2015) by activating the hypoxia sig-
nalling pathway. Indeed, a recent study has shown that in bone,
physiological oxygen concentrations can be as low as 1.3% or
10 mmHg (Spencer et al., 2014), which are much lower than the
ambient oxygen levels that we breathe (21% or 160 mmHg).
Moreover, activation of the hypoxia signalling pathway is known to
increase exponentially as oxygen concentrations fall below 8% or
60 mmHg (Ehrismann et al., 2007). A better understanding of the
processes activated by the hypoxia signalling pathway in skeletal
cells may therefore provide novel options to improve bone tissue
engineering strategies.response in bone tissue engineering: A balance between supply and
crinology (2016), http://dx.doi.org/10.1016/j.mce.2015.12.024
P.-J. Stiers et al. / Molecular and Cellular Endocrinology xxx (2016) 1e102In this review, wewill discuss the current knowledge on hypoxia
signalling in bone regeneration and wewill provide an overview of
the different strategies that are being explored in bone tissue en-
gineering to overcome cell death after implantation due to the
long-lasting and extensive hypoxia, including pro-angiogenic
therapies, prevascularization strategies and cellular
preconditioning.
2. Bone tissue engineering
While bone has a tremendous regeneration potential and is one
of the few tissues that can heal completely without scar formation,
10% of fractures results in a non-union (Tytherleigh-Strong et al.,
1997). In case of congenital defects, like neuroﬁbromatosis 1, or
surgical resection, this regenerative potential may become even
more challenged and often leads to inadequate healing, which
causes an enormous health care burden. The current gold standard
treatment consists of bone auto- or allografts, but several problems
restrict their usefulness including the limited availability at the
harvest site, incomplete integration into the defect and risk of
disease transfer (Delloye et al., 2007). A promising therapeutic
alternative for autografts in large bone defects is bone tissue en-
gineering, which is a branch of regenerative medicine that aims to
create new bone tissue from osteogenic stem or progenitor cells
seeded on an osteoconductive carrier or scaffold, often in combi-
nation with osteoinductive growth factors.
The bone-forming cells frequently used for tissue engineering
are the mesenchymal stromal cells (MSC, also known as mesen-
chymal stem cells). Bonemarrow-derived MSC are usedmost often,
although it are the periosteum-derived cells that primarily
contribute to fracture healing and are therefore increasingly being
studied (Colnot, 2009; Gomez-Barrena et al., 2011). Indeed, human
and mouse periosteum-derived cells were considered much more
difﬁcult to obtain than bonemarrow-derived cells, but protocols for
their isolation have been developed and can now be routinely used
(De Bari et al., 2006; van Gastel et al., 2012). These cells highly
express classical MSC markers, show trilineage potential in vitro
and contribute extensively to bone regeneration in vivo, making
them exceptionally suited for bone tissue engineering strategies
(Roberts et al., 2015). Adipose-derived MSC and embryonic or
induced pluripotent stem cells are also being actively explored as
cell source because of their greater availability. However, their
in vivo bone-forming potential has not been as rigorously studied as
for the bone-derived MSC (reviewed in (Robey, 2011)).
Numerous materials are used as carriers for these cells: they
range from biological materials designed to closely mimic the
composition of bone (i.e. calcium phosphate and collagen) over
synthetic polymers (e.g. polylactic acid, polycaprolactone) to
bioactive glass and metals, and many types of composite designs.
Most scaffold materials can be chemically treated or biologically
functionalized with peptides to enhance their osteoconductivity,
degradability and angiogenic response. As the focus of this review
is on the hypoxic response as a potential therapeutic target, we
refer the reader for more information on biomaterial characteristics
and their functionalization to some recent excellent reviews (Bose
et al., 2012; Wu et al., 2014).
Finally, certain growth factors that have been described to be
crucial for fracture healing are also being used for bone tissue en-
gineering (reviewed in (Gothard et al., 2014)). Perhaps the most
important examples are the bone morphogenic proteins (BMPs),
notably BMP-2. They are currently approved for spinal fusion and
open tibia fractures, although application of high-dosed BMP alone
has proven not to be as safe as initially believed (Shields et al.,
2006). Angiogenic growth factors, such as vascular endothelial
growth factor (VEGF) or placental growth factor, are also crucial forPlease cite this article in press as: Stiers, P.-J., et al., Targeting the hypoxic
consumption to improve bone regeneration, Molecular and Cellular Endofracture repair and can be used to induce angiogenesis in bone
tissue-engineered constructs. Several other factors, like ﬁbroblast
growth factors or transforming growth factors, can act on both
osteo- and angiogenesis (reviewed in (Stegen et al., 2015)). How-
ever, when these factors are used as monotherapy for bone repair,
they often have to be applied in high doses and frequently result in
adverse side effects such as soft tissue inﬂammation and swelling,
haematoma formation, heterotopic ossiﬁcation and induction of
osteolysis. These complications seriously limit their clinical appli-
cability (Epstein, 2011; Shields et al., 2006). Nevertheless, these
growth factors may potentially be used at much lower doses when
they are combined with cell-based constructs. It is hypothesized
that this reduced dose may be sufﬁcient to stimulate primarily the
bone forming potential of the implanted cells, although supporting
clinical evidence is still lacking. Alternatively, the use of growth
factors can be restricted to the pre-implantation cell expansion
phase in order to enhance the regenerative potency of the
implanted MSC and thereby prevent possible side effects caused by
in vivo application of growth factors (van Gastel et al., 2014).
To summarize, bone tissue engineering is an expansive ﬁeld
with new combination approaches being developed continuously.
However, the therapeutic success of clinically relevant regenerative
implants will largely depend on how the implanted cells are
adapted to react to the hostile and hypoxic host environment into
which they are placed.
3. The hypoxia signalling pathway
The crucial mediators of hypoxia signalling are Hypoxia Induc-
ible Factor 1 (HIF-1) and HIF-2, heterodimeric transcription factors
consisting of an a and b subunit. Both subunits are constitutively
expressed in most tissues and cells, but the HIF-a subunit is turned
over very rapidly at the protein level under normoxic conditions
(Fig. 1). When sufﬁcient oxygen is available, HIF-1a is hydroxylated
by proline hydroxylase domain (PHD)-containing enzymes (PHD1,
PHD2, PHD3), of which PHD2 appears to be the main effector for
HIF-1 activity (Appelhoff et al., 2004; Berra et al., 2003). These
enzymes use oxygen and a-ketoglutarate as substrates and ferrous
iron and ascorbate as cofactors. Upon hydroxylation of HIF-1a, the
Von Hippel-Lindau protein (VHL) ubiquitinates the N- and C-ter-
minal oxygen dependent degradation domains of HIF-1a, causing
HIF-1a to be targeted for proteasomal degradation (Maxwell et al.,
1999). As a result, HIF-1a is a highly unstable protein in aerobic
conditions. When oxygen tension decreases, the PHDs will become
less active, resulting in stabilization of HIF-1a which can then bind
to HIF-b and exert its transcriptional activity in the nucleus (Huang
et al., 1998). Reduced activity of PHDs through lowered oxygen
concentration is however not the only mechanism that can induce
HIF stabilization. Certain hormones and growth factors, such as
angiotensin II, epidermal growth factor and insulin-like growth
factor can induce HIF-mediated signalling in normoxic conditions
via activation of protein kinase C and phosphatidylinositol-3 kinase
(Fukuda et al., 2002; Richard et al., 2000; Zhong et al., 2000).
Interestingly, the osteochondrogenic Runt-related transcription
factor 2 (Runx2) also directly increases HIF-1a activity in MSC and
hypertrophic chondrocytes by competing with VHL (Kwon et al.,
2011; Lee et al., 2012). Hypoxia signalling can also be chemically
induced by using small molecules that block PHD activity; most of
them interfere with cofactor or substrate availability (e.g. iron
chelators, a-ketoglutarate analogues) and therefore not only target
PHDs, but speciﬁc PHD inhibitors are actively being developed.
The HIF complex transactivates genes containing one or more
hypoxia response elements (5ʹ-[A/G]CGTG-30), of which more than
100 have been identiﬁed to date. These genes are mainly involved
in the regulation of energy metabolism, angiogenic response,response in bone tissue engineering: A balance between supply and
crinology (2016), http://dx.doi.org/10.1016/j.mce.2015.12.024
Fig. 1. Overview of the hypoxia signalling cascade mediated by Hypoxia Inducible Factor 1a (HIF-1a). Under normoxia, HIF-1a is rapidly hydroxylated by proline hydroxylase
domain (PHD)-containing enzymes which use oxygen (O2) and a-ketoglutarate (a-KG) as substrates. HIF-1a is then ubiquitinated (Ub) by interaction with the Von Hippel-Lindau
protein (VHL), and is targeted for proteosomal degradation. When oxygen tension decreases, PHDs become inactive and HIF-1a will accumulate and translocate to the nucleus,
where it can exert its transcriptional activity together with HIF-1b by binding to hypoxia response elements (HRE) in genes like glucose transporter 1 (Glut1) or vascular endothelial
growth factor (VEGF).
P.-J. Stiers et al. / Molecular and Cellular Endocrinology xxx (2016) 1e10 3erythropoiesis and cell survival; examples include glucose trans-
porter 1, VEGF and erythropoietin. There are three known HIF-a
subunits, of which HIF-1a is the best studied. HIF-2a undergoes the
same proteolytic degradation and appears to regulate a set of genes
overlapping with HIF-1a (Flamme et al., 1997), but it also controls
speciﬁc target genes and differs from HIF-1a in its spatial expres-
sion pattern, indicating that HIF-2a may act on different processes
(Ema et al., 1997; Hu et al., 2003; Wiesener et al., 2003). With
respect to skeletal development and homeostasis, both factors have
been shown to regulate these processes differentially (Saito et al.,
2010; Shomento et al., 2010). HIF-3a, on the other hand, is not
closely related to the others and functions mainly as a negative
regulator of HIF-mediated gene expression as it lacks transcrip-
tional activator domains (Makino et al., 2001).4. Hypoxia in bone repair
Bone repair recapitulates many of the molecular pathways
regulating bone development and these processes are also of in-
terest to successfully engineer bone (Gerstenfeld et al., 2003). In all
these instances, bone is formed either directly by committed
osteoblast progenitors through intramembranous ossiﬁcation, orPlease cite this article in press as: Stiers, P.-J., et al., Targeting the hypoxic
consumption to improve bone regeneration, Molecular and Cellular Endovia endochondral bone formationwhere a cartilage template is ﬁrst
formed. The chondrocytes in this template will produce a carti-
laginous matrix and then hypertrophy and undergo apoptosis,
which coincides with mineralization of the matrix and vascular
invasion. Several genetic mouse studies have underscored the
importance of HIF signalling in skeletal development and regen-
eration, both through its regulation of tissue vascularization, which
we will discuss ﬁrst, as well as through cell-autonomous effects
discussed in a subsequent section.
During bone growth, conditional deletion of VHL in osteoblasts
resulted in stabilization of HIF, enhanced VEGF expression,
increased angiogenesis and a higher bone mass, whereas mice
lacking HIF-1a in osteoblasts had reduced vasculature and bone
volume (Wang et al., 2007). Upon fracture or trauma the blood
supply to the injured bone is disrupted greatly, resulting in hypoxia
in the surrounding cells and haematoma formation. These events,
together with the elicited inﬂammatory reaction lead to a strong
angiogenic response in the damaged tissue, which will ultimately
secure the supply of oxygen, nutrients and growth factors
(reviewed in (Stegen et al., 2015)). The importance of enhanced
angiogenesis for bone repair has been evidently shown by different
animal models and clinical observations (Brinker and Bailey, 1997;response in bone tissue engineering: A balance between supply and
crinology (2016), http://dx.doi.org/10.1016/j.mce.2015.12.024
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2006). We and others have shown that periosteum-derived cells
are likely contributing to this reaction, as they are able to mount a
strong pro-angiogenic and osteogenic response following exposure
to hypoxia in vitro (Ichijima et al., 2012; van Gastel et al., 2012). In
addition, activation of the HIF pathway also contributes to
improved bone regeneration, as shown in a model of distraction
osteogenesis, where enhanced hypoxia signalling in osteoblasts
leads to better vascularization and bone regeneration in a VEGF-
dependent manner (Wan et al., 2008). Moreover, compounds that
induce hypoxia signalling are reported to promote fracture healing
in rodents (Shen et al., 2009; Wan et al., 2008).
However, the effects of hypoxia signalling in bone development
are likely not exclusively mediated via increasing angiogenesis, as
has been shown in several developmental and in vitro studies. For
instance, the growth plate is an avascular tissue and upon size
expansion, the centrally localized chondrocytes need HIF signalling
to adapt to and survive in the developing low-oxygen environment
(Provot et al., 2007; Schipani et al., 2001). However, the HIF null
mouse phenotype is only partially rescued by VEGF overexpression
and the associated increase in angiogenesis, suggesting that other
unidentiﬁed mechanisms are involved (Maes et al., 2012; Schipani
et al., 2001). Consistent herewith, deletion of the soluble isoforms
of VEGF, which are directly regulated by HIF, negatively affects
chondrocyte survival in the hypoxic centre, not only by delaying
vascular invasion, but also in a cell-autonomous manner (Maes
et al., 2004). A possible mechanism is that HIF signalling in chon-
drocytes regulates the expression of collagen processing enzymes, a
pathway that may contribute to preservation of extracellular ma-
trix production and indirectly to chondrocyte survival (Aro et al.,
2012).
Numerous in vitro studies have reported on the direct,
angiogenesis-independent, role of hypoxia signalling for the dif-
ferentiation of MSC to osteoblasts and for the function of mature
osteoblasts, but data are inconsistent (an overview of recent liter-
ature is provided in Table 1). The differences in oxygen level,
duration and timing of hypoxia during cell culture, cell source and
cell parameters studied may explain the variability in cellular re-
sponses observed between the different studies. It is therefore
difﬁcult to draw a conclusion from the plethora of data reported,
but in general, in vitro models of moderate-low oxygen tension
(3e5% oxygen) appear to correlate with positive effects on osteo-
blast proliferation and differentiation, whereas more severe hyp-
oxia negatively regulates these osteoblast properties. Besides these
in vitro data suggesting a cell-autonomous effect of hypoxia sig-
nalling in osteogenic cells, recent in vivo observations also point to
direct changes in osteoblasts. When HIF signalling was induced in
osteochondral progenitor cells or mature osteoblasts in vivo, the
increase in bone mass was associated with an increase in the pro-
liferation and number of osteoblasts, although these ﬁndings were
not demonstrated to be angiogenesis-independent (Wang et al.,
2007; Weng et al., 2014). Recent evidence highlights that meta-
bolic adaptations in osteoblasts, resulting in activation of glycolysis,
are essential for the increased bone formation when HIF-1a is
stabilized in osteoprogenitors postnatally (Regan et al., 2014).
Furthermore, HIF activation by deleting PHD2 and PHD3 in osteo-
progenitors enhanced the expression of osteoprotegerin, an
osteoclast-inhibiting factor, and the associated decrease in osteo-
clast formation resulted in increased accumulation of bone mass
(Wu et al., 2015). However, one has to be cautious to extrapolate
these ﬁndings to bone tissue engineering, as these studies were
performed by activating HIF signalling in cells experiencing a well-
vascularized environment. It remains therefore to be shown
whether the HIF pathway will be sufﬁcient for implanted cells to
adapt to a microenvironment devoid of oxygen and/or nutrients,Please cite this article in press as: Stiers, P.-J., et al., Targeting the hypoxic
consumption to improve bone regeneration, Molecular and Cellular Endowhich they encounter after implantation.
Taken together, hypoxia signalling plays an important role in the
formation, maintenance and regeneration of bone by angiogenesis-
dependent and -independent mechanisms.
5. Hypoxia in bone tissue engineering
A timely and sufﬁciently strong hypoxia response is thus needed
during bone repair to stimulate angiogenesis and bone formation.
However, the process of angiogenesis is an inherently slow process
(estimates range from 100 mm to 1 mm per day (Mikos et al., 1993;
Orr et al., 2003)), and the timely generation of a stable vascular
network has long been identiﬁed as a fundamental challenge for
tissue engineering (Koike et al., 2004). Because of the inherent
constraints of vascular ingrowth, constructs of clinically relevant
size may progressively become devoid of oxygen and nutrients in
their centre upon implantation, which will be detrimental for
cellular function and survival (Radisic et al., 2006; Scheuﬂer et al.,
2008). For this reason, a major research focus lies on either
increasing the availability of oxygen or reducing its need in large
tissue engineering constructs.
6. Reducing hypoxia through extrinsic angiogenesis
As the lack of blood vessel perfusion is a main contributor to
hypoxia in tissue-engineered constructs, speeding up the process of
(re)vascularization is an attractive strategy to remedy this problem
(Fig. 2A). Extrinsic or host-driven vascularization can be stimulated
through local administration of VEGF (Takeshita et al., 1994). As it is
the main angiogenic growth factor in fracture healing, VEGF has
been shown to enhance bone regeneration (Street et al., 2002;
Tarkka et al., 2003). However, safety concerns exist over the use
of high-dosed VEGF (Lee et al., 2000; Maes et al., 2010; Vajanto
et al., 2002), which may lead to ﬁbrosis and abnormal blood
vessel formation and function. Nevertheless, by optimizing this
approach, VEGF can be used to improve angiogenesis in a bone
tissue-engineered construct when applied in a more sustained,
low-dose regimen. This strategy can be achieved either through
functionalization of the scaffold with VEGF (Detsch et al., 2014;
Jabbarzadeh et al., 2012) or through its genetically induced
expression by the implanted cells (Feng et al., 2013; Helmrich et al.,
2013). Besides VEGF, other factors like thrombin and pleiothropin
appear to have beneﬁcial effects. Indeed, data from in vitro exper-
iments with thrombin and in vivo experiments with pleiothropin
respectively indicate that these factors enhance the angiogenic and
osteogenic response of mesenchymal cell lines and human bone-
marrow derived MSC (Bluteau et al., 2006; Yang et al., 2003).
Furthermore, adaptations to scaffold material, design and porosity
can be used to stimulate blood vessel ingrowth. For instance, the
pore size of the scaffold is an important property that inﬂuences
the in vivo osteogenic response, where small pores (<100 mm) will
result in a hypoxic environment that favours cartilage formation,
whereas larger pores (>300 mm) are more readily vascularized and
promote direct bone formation (Karageorgiou and Kaplan, 2005).
Thus, adaptations in timing and dosing of administered angiogenic
growth factors as well as optimization in scaffold properties may
improve adequate and timely blood vessel ingrowth into the
scaffold.
7. The potential of intrinsic angiogenesis to decrease hypoxia
Establishing a vascular network from within the construct, or
intrinsic vascularization, is an alternative approach that may help
overcome detrimental hypoxia in a tissue-engineered construct.
Instead of relying on growth factors to attract blood vessels fromresponse in bone tissue engineering: A balance between supply and
crinology (2016), http://dx.doi.org/10.1016/j.mce.2015.12.024
Table 1
Overview of the effect of hypoxia on proliferation and differentiation of osteoblasts and osteoblast progenitors.
Reference Cell type Hypoxia model Timing Proliferation ALP Runx2 Col1 OCN Mineralization
Primary osteoblasts (in vitro)
Warren et al., 2001 rat calvaria OB 5% O2 Expansion (48 h) [
Utting et al., 2006 rat calvaria OB 2% O2 Expansion (6-18 d) Y
2% O2 Differentiation
(18 d)
Y Y
Salim et al., 2004 mouse calvaria OB 2% O2 Preconditioning
(24 h)
¼ ¼ ¼ ¼
<0.1% O2 Preconditioning
(24 h)
Y Y Y Y
Wang et al., 2007 mouse calvaria OB VHL KO Both (14 d) ¼ ¼ ¼ ¼ ¼
Primary MSC (bone marrow-derived, in vitro)
Boyette et al., 2014 human BMSC 5% O2 Expansion (4 d) [
5% O2 Differentiation
(21 d)
[ [ [ [
Zhou et al., 2013 rat BMSC 5% O2 Expansion (14 d) [ [ [
Berniakovich and Giorgio,
2013
mouse BMSC 3% O2 Both (21 d) [ [
Fehrer et al., 2007 human BMSC 3% O2 Both (21 d) [ Y
Wagegg et al., 2012 human BMSC 2% O2,
DFO, DMOG
Differentiation
(28 d)
[ [
Tsai et al., 2011 human BMSC 1% O2 Both (21 d) [ [
Park et al., 2013 human BMSC 1% O2 Both (28 d) [ Y Y
Yang et al., 2011 human BMSC 1% O2 Both (21 d) Y Y
Hsu et al., 2013 human BMSC 1% O2 Differentiation
(21 d)
Y Y Y
Cicione et al., 2013 human BMSC 1% O2 Differentiation
(21 d)
Y Y
Lee et al., 2015 human vertebral BMSC 1% O2 Both (21 d) Y Y Y [
Li et al., 2015 mouse BMSC 1% O2 Expansion (24 h) [
Xu et al., 2013 rat BMSC 1% O2 differentiation
(21 d)
Y Y Y Y
Primary MSC (other sources, in vitro)
Ichijima et al., 2012 rat calvaria PDC 5% O2 Both (72 h) ¼ [ [ [
Fotia et al., 2015 human adipose-derived
MSC
3% O2 Both (14 d) [ [ [
Zhang et al., 2014 human periodontal cells 2% O2 Both (21 d) [
Xu et al., 2014 rabbit adipose-derived
MSC
1% O2 Both (28 d) [ [ [ [
Ding et al., 2014 rat adipose-derived MSC DMOG Both (21 d) Y [ [ [ [
Mesenchymal cell lines (in vitro)
Chen et al., 2012 MC3T3 1% O2 Expansion (72 h) Y Wnt signalling activity Y
Chen et al., 2013 MC3T3 1% O2 Expansion (48 h) SOST expression [
Zhou et al., 2015 C3H10T1/2 HIF-1a overexpression Differentiation (9 d) Y Y
Peng et al., 2014 C3H10T1/2 DMOG Differentiation
(21 d)
[ [ [
Sugrue et al., 2014 commercial cell lines 5% O2 Expansion (7 d) [
Pattappa et al., 2013 commercial cell lines 5% O2 Both (21 d) Y Y Y
Volkmer et al., 2010 commercial cell lines 2% O2 Both (21 d) [ Y Y
In vivo genetic mouse models
Regan et al., 2014 OSX e HIF1-PPN HIF-1a overexpression in
osteoprogenitors
5w old ¼ More osteoblasts
Weng et al., 2014 Col2-cre VHLﬂox VHL KO in osteochondral progenitors 16w old [ More osteoblasts
Wang et al., 2007 OCN-cre VHLﬂox VHL KO in mature OB 3w old More osteoblasts
Zuo et al., 2015 OCN-cre VHLﬂox VHL KO in mature OB 6w old [ b-catenin and Osterix expression [
Abbreviations used: alkaline phosphatase (ALP), bone marrow-derived mesenchymal stromal cell (BMSC), type I collagen (Col1), type II collagen (Col2), deferoxamine (DFO),
dimethyloxallyl glycine (DMOG), hypoxia inducible factor 1a (HIF-1a), knockout (KO), mesenchymal stromal cell (MSC), osteoblast (OB), osteocalcin (OCN), osterix (OSX),
periosteum-derived cell (PDC), runt-related transcription factor 2 (Runx2), sclerostin (SOST), Von Hippel-Lindau protein (VHL). Timing reﬂects when and for how long in hours
or days hypoxia was applied before analysis: short-term hypoxia (expansion), hypoxia only during osteogenic differentiation conditions but not during expansion (differ-
entiation), hypoxia both during expansion and differentiation (both), and hypoxia during expansion but not subsequent differentiation (preconditioning). Effects are shown as
increased ([), decreased (Y) or unchanged (¼) compared to controls.
P.-J. Stiers et al. / Molecular and Cellular Endocrinology xxx (2016) 1e10 5the host into the implant, scaffolds can be microfabricated to
contain small hollow ﬁbres or capillary structures that mimic the
morphology of blood vessels and may serve as a template for
vascularization (Fidkowski et al., 2005; Moroni et al., 2006).
Furthermore, instead of using only osteoblast progenitors, the
additional incorporation of endothelial (progenitor) cells into
tissue-engineered constructs is a possible approach (Fig. 2B). The
idea behind this strategy is that when these two cell populations
are seeded on a scaffold, the endothelial compartment will form a
vascular network through so-called in vitro prevascularization.Please cite this article in press as: Stiers, P.-J., et al., Targeting the hypoxic
consumption to improve bone regeneration, Molecular and Cellular EndoUpon implantation, this network then only has to anastomose to
the host vasculature to establish perfusion. Indeed, many studies
have shown that implanted endothelial cells can contribute to the
blood vessels that are formed inside tissue-engineered constructs
(Koike et al., 2004; Ma et al., 2014a; van Gastel et al., 2012). While
promising, most approaches are still in an experimental stage with
varying degrees of success, even in small defects (Kim and von
Recum, 2008). An important consideration for the engineering of
blood vessel networks is that they will face regression without
adequate stabilization by mural cells (Gerhardt and Betsholtz,response in bone tissue engineering: A balance between supply and
crinology (2016), http://dx.doi.org/10.1016/j.mce.2015.12.024
Fig. 2. Schematic overview of experimental strategies related to vascularization and hypoxia signalling that can enhance bone regeneration in a tissue-engineered construct. A.
Application of angiogenic growth factors or adaptations in scaffold designs can increase vascularization by the host. B. Implantation of endothelial stem/progenitor cells may allow a
vascular network to form from within the construct. C. Induction of hypoxia signalling prior to implantation can elicit a beneﬁcial stress response that may improve therapeutic
potency through enhanced survival, proliferation or differentiation of the implanted cells. D. Engineering of a cartilage template, as chondrocytes may survive better in an avascular
environment. This approach may lead to bone formation through endochondral ossiﬁcation.
P.-J. Stiers et al. / Molecular and Cellular Endocrinology xxx (2016) 1e1062003). Interestingly, mesenchymal and endothelial cells show a
positive interaction already during 2D culture via a mechanism that
is not exclusively regulated by VEGF (Villars et al., 2000), indicating
that mesenchymal cells may contribute a perivascular component
that stabilizes the formed blood vessels (Melero-Martin et al.,
2008; van Gastel et al., 2012).
In conclusion, increased vascularization can be obtained
through the use of angiogenic growth factors, endothelial cells, and
scaffold design. While each of these strategies individually has
proven to be beneﬁcial for the supply of oxygen to a bone tissue-
engineered construct, a combination approach may be required
to achieve a viable implant of clinically relevant size.8. Modulating hypoxia signalling pathways as a cellular
protection strategy
While many strategies are aimed to prevent hypoxia in a large
tissue-engineered construct, hypoxia signalling itself can also be
invoked more prominently to improve the therapeutic outcome of
a tissue-engineered construct. This effect can be obtained through
hypoxic preconditioning (Fig. 2C), inhibition of negative regulators
of HIF-1a (PHDs and VHL) in cells prior to implantation, or direct
overexpression of HIF. Hypoxia preconditioning is a cellular adap-
tive mechanism elicited by sublethal exposure of cells to low oxy-
gen concentrations (Murry et al., 1986). The stress response thatPlease cite this article in press as: Stiers, P.-J., et al., Targeting the hypoxic
consumption to improve bone regeneration, Molecular and Cellular Endofollows will protect cells against subsequent hypoxic insults, lead-
ing to improved function and survival through upregulation of anti-
apoptotic and pro-angiogenic factors in, for example, stem cell-
based treatment of myocardial infarction (Azarnoush et al., 2005;
Hu et al., 2008), ischaemic disease in limb and brain (Bhang et al.,
2011; Rey et al., 2011; Theus et al., 2008) or spinal cord injury
(Oh et al., 2010).
For applications in bone tissue engineering, overexpression and
small molecule-induced stabilization of HIF-1a have been demon-
strated to increase angiogenesis and subsequent bone regeneration
in tissue-engineered constructs (Ding et al., 2014; Zou et al., 2011),
but it remains unexplored whether enhanced angiogenesis is the
only contributing factor in these models. A recent study demon-
strates that hypoxic preconditioning of bone marrow stromal cells
enhances in vivo bone formation in a bone tissue-engineered
construct, which was associated with increased collagen matrix
abundance (Lee et al., 2015). Finally, in vitro data show that the
incorporation of PHD or VHL inhibitors into the scaffold structure
may lead to the stabilization of HIF in the seeded cells, which in
turn can increase the expression of VEGF and promote the differ-
entiation towards the osteogenic lineage. Examples include bioac-
tive glass functionalized with dimethyloxallyl glycine (DMOG; (Wu
et al., 2013)) which blocks PHDs, or with cobalt (Quinlan et al.,
2015) which inhibits PHD activity. Because the small molecules
used thus far to stabilize HIF-1a do not only target PHD speciﬁcally,response in bone tissue engineering: A balance between supply and
crinology (2016), http://dx.doi.org/10.1016/j.mce.2015.12.024
P.-J. Stiers et al. / Molecular and Cellular Endocrinology xxx (2016) 1e10 7one has to be cautious about off-target and unspeciﬁc effects.
Taken together, most studies on hypoxia signalling in bone tis-
sue engineering mainly focus on angiogenesis, which is important
for bringing oxygen and nutrients into the implant in order to
sustain the viability of the implanted cells, and therefore the overall
success of the implant. However, an increasing number of reports
on other cell types show that hypoxia signalling can also affect the
implanted cells directly, either through increasing cell survival, or
through regulation of cellular proliferation and differentiation.
Careful dissection of these processes will allow optimization of
bone tissue engineering construct combinations with improved
viability and regenerative potential.
9. Endochondral bone formation as a physiological
adaptation against hypoxia
The studies discussed above focus largely on the generation of
tissue-engineered constructs that promote bone formation through
the intramembranous pathway. However, most of our bones form
through the endochondral bone formation process during devel-
opment. Recapitulating this process as a strategy for bone tissue
engineering, known as developmental engineering (Lenas et al.,
2009), may circumvent many of the problems that are related to
the harmful hypoxia in tissue engineering constructs. In this
approach, a cartilaginous template is engineered instead of
implanting cell-based constructs that form bone directly (Fig. 2D).
Indeed, implantation of a chondrogenic construct can spontane-
ously induce the subsequent formation of mineralized tissue,
reminiscent of what is seen during endochondral bone formation
(Harada et al., 2014; Tam et al., 2014; van Gastel et al., 2014; Weiss
et al., 2012). Moreover, endochondral ossiﬁcation can also be
induced using cell-free implants obtained by devitalizing chon-
drogenic constructs, especially when matrix characteristics and the
presence of growth factors to attract host cells are preserved
(Bourgine et al., 2014). Furthermore, while the effect of hypoxia on
osteogenic differentiation is not yet fully clear, the activation of
hypoxia signalling in chondrocytes (Pfander et al., 2004) leads to
higher expression of cartilage markers during in vitro culture (Shi
et al., 2015; Strobel et al., 2010; Zhou et al., 2015), as well as
improved collagen cross-linking during matrix synthesis (Makris
et al., 2014) despite lowering of the proliferation of chondrocytes.
In this way, engineering of endochondral bone tissue makes use of
the physiological role of hypoxia signalling during bone develop-
ment and the potential of chondrocytes to survive and differentiate
in an avascular environment.
10. Conclusion & future perspectives
Bone tissue engineering has as its goal to mimic the repair
process in bone, which in turn greatly resembles bone develop-
ment. In bone development and repair, hypoxia signalling has a
crucial role, and many studies have focussed on the link between
angiogenesis and bone formation which is largely mediated by
VEGF, a target gene of the HIF pathway. Increasing angiogenesis in a
bone construct of clinically relevant size will favour bone forma-
tion, as survival, proliferation and differentiation of the implanted
cells are dependent on sufﬁcient oxygen and nutrient supply (Feng
et al., 2013; van Gastel et al., 2012; Zou et al., 2011). However,
because blood vessel formation is an inherently slow process,
completely preventing harmful hypoxia through neoangiogenesis
alone may prove difﬁcult.
In addition to vascular effects, hypoxia signalling mediates re-
sponses that alter cell metabolism, survival and differentiation
directly. Current literature points towards positive effects of hyp-
oxia signalling on undifferentiated MSC during in vitro culture (TsaiPlease cite this article in press as: Stiers, P.-J., et al., Targeting the hypoxic
consumption to improve bone regeneration, Molecular and Cellular Endoet al., 2011; Volkmer et al., 2010), where it promotes the preser-
vation of the proliferative and multipotency capacities of MSC, but
the effect of hypoxia signalling on differentiating and mature os-
teoblasts has not been as conclusively determined. In other tissue
models of regenerative MSC-based therapies, hypoxia signalling
enhances the in vivo outcome (Huang et al., 2014; Rey et al., 2011)
by improving cell survival through adapting energy, pH and redox
balance. Whether these adaptations would also prove beneﬁcial in
a bone tissue engineering strategy remains to be shown. It is
important to note that these cell-autonomous effects do not
depend on slow, partially host-driven processes such as angio-
genesis, but instead may protect the implanted cells against the
stressful environment much more rapidly and continuously.
Furthermore, the cell-protective and pro-angiogenic effects of
hypoxia signalling are notmutually exclusive andmay even be used
in synergy to enhance tissue regeneration. Finally, while enhancing
angiogenesis may require (co-)implantation of additional factors or
cells to attract blood vessels, hypoxic preconditioning to enhance
bone formation can be done through pre-treatment alone, without
requiring further manipulations or additions to the tissue-
engineered construct.
In conclusion, hypoxia signalling mediates a protective response
consisting of a pro-angiogenic and a pro-survival component,
where the beneﬁt of the angiogenic response has been well
described in bone tissue engineering. The effects on metabolism,
survival and differentiation of the implanted cells themselves have,
however, been much less studied, but still offer many exciting op-
portunities to improve the therapeutic potential of bone tissue
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